05:33 PM EDT, 04/08/2026 (MT Newswires) -- Vanda Pharmaceuticals ( VNDA ) initiated a clinical trial evaluating Nereus for the prevention of vomiting in patients receiving GLP-1 receptor agonist therapies.

The randomized, double-blind, placebo-controlled trial will assess the safety and efficacy of oral Nereus in patients starting high-dose GLP-1 therapy, with the primary endpoint being the percentage of patients who remain free from vomiting, Vanda said Wednesday in a statement.

Phase 2 results showed the drug reduced vomiting by 50% compared with placebo, supporting continued development in this indication, the company said.

Vanda expects topline results from the study in Q4.